Neonatal Direct Antiglobulin Test Interpreter

The newborn direct antiglobulin test read with the maternal and infant blood group and the antibody identified — because a positive DAT does not by itself mean haemolysis, and a negative one does not exclude ABO haemolytic disease.

Last updated 16 Sep 2026

Neonatal DAT with blood groups and antibody

DAT + groups + antibody → interpretation

Direct antiglobulin test resultNICE CG98 asks you to ‘interpret the result taking account of the strength of reaction, and whether mother received prophylactic anti-D immunoglobulin during pregnancy’. No published grade of reaction is a haemolysis threshold, so the strength is offered here as context rather than as a cut-off: a weak positive in an ABO-incompatible baby is common and usually clinically silent, and a strong positive is not a diagnosis of haemolysis either.

Maternal and infant blood groupBoth groups are required by NICE CG98 as part of the assessment for underlying disease in significant hyperbilirubinaemia, alongside the serum bilirubin, the packed cell volume and the DAT itself. ABO incompatibility of the O-mother/A-or-B-baby kind is by far the commonest, and it is the one in which the DAT performs worst in both directions.

Antibody identifiedThe specificity changes the disease, not just the label. Anti-D, anti-c and anti-K are the three the British Society for Haematology names as associated with significant fetal and neonatal risk. Anti-K is different in kind from the others: it suppresses erythropoiesis rather than simply haemolysing, so the anaemia can be severe while the reticulocytes are low and the bilirubin modest.

Did the mother receive prophylactic anti-D immunoglobulin?This is the single most consequential question on the page. Passively acquired anti-D from routine antenatal prophylaxis coats the RhD-positive baby’s red cells and produces a positive DAT that is not haemolytic disease. AAP 2022 encodes this directly: its neurotoxicity risk factor is a ‘positive direct antiglobulin test, if Rh(D) immune globulin was not given during pregnancy’, because the immune globulin itself can cause the positive result.

Positive DAT with ABO incompatibilityExample

Positive DAT in a group A baby of a group O mother, anti-A identified, no anti-D prophylaxis given

How well the DAT performs in ABO haemolytic disease

Read the first and last blocks together. One ABO-HDFN in three is DAT negative, and two in three positive DATs do not produce early significant jaundice. The test stratifies risk usefully — a positive DAT nearly septuples the odds of needing phototherapy — and it neither makes nor excludes the diagnosis.
Measure	Figure	Study
Sensitivity	65.85%	Nested case-control, 4,122 newborns, 44 with ABO-HDFN
Specificity	96.28%	Same study
Positive predictive value	16.9%	Same study
Negative predictive value	99.6%	Same study
ABO-HDN cases that were DAT negative, identified by elution	143 of 156 (91.67%)	Retrospective series, tertiary children’s hospital
ABO-incompatible newborns with a positive DAT	68 of 426 (15.9%)	2,484 live births, cord DAT series
Of those DAT-positive babies, needing phototherapy within 24 hours	23 of 68 (33.8%)	Same series
Odds ratio for phototherapy-requiring hyperbilirubinaemia if DAT positive	6.78 (95% CI 2.38 to 19.33)	158 blood-type-incompatible infants

Which antibodies matter

The severity column is a property of the population, not of the baby in front of you: ABO disease sits under ‘mild’ and still results in exchange transfusion. The last row is the one that changes what you measure rather than how worried you are.
Severity of HDFN	Antigens
Associated with severe HDFN	D, C, c, E (Rh); K, k (Kell); Fya (Duffy); Jka, Jkb (Kidd); M, S (MNS)
Associated with mild HDFN	A, B (ABO); i (Ii); Fyb (Duffy); Lua, Lub (Lutheran)
Not associated with HDFN	Lea, Leb (Lewis); I; P1
Named by the British Society for Haematology as carrying significant fetal and neonatal risk	Anti-D, anti-K, anti-c
Acts by suppressing erythropoiesis rather than haemolysis	Anti-K, and by a related mechanism anti-M

Why anti-K is different

Every marker that would normally warn you is biased downwards by anti-K: the reticulocytes, the bilirubin and the maternal titre. Some authors argue anaemic disease of the fetus and newborn is the more accurate name for it. The practical consequence is that the haemoglobin, not the bilirubin, is the number to follow.
Feature	Anti-D and the other haemolytic antibodies	Anti-K
Mechanism	Immune destruction of circulating red cells	Suppression of fetal erythropoiesis at the progenitor level, with in vitro inhibition of Kell-positive BFU-E and CFU-E
Reticulocyte count	Raised, in proportion to the anaemia	Low, ‘corresponding to the severity of their anemia’
Bilirubin	Tracks the haemolysis	Lower than the anaemia would suggest
Maternal titre against fetal anaemia	Correlates	‘Poor correlation between maternal antibody titer and the degree of anemia’
Dominant presentation	Hyperbilirubinaemia	‘More severe fetal anemia and hydrops, rather than hyperbilirubinemia’

The investigations NICE CG98 asks for in significant hyperbilirubinaemia

The DAT is one of four required tests and is not the one that makes the diagnosis. The instruction attached to it — interpret it against the strength of reaction and against maternal anti-D prophylaxis — is the guideline’s own acknowledgement that a positive result has more than one cause.
Test	Status
Serum bilirubin	Required — baseline level to assess response to treatment
Blood packed cell volume	Required
Blood group, mother and baby	Required
DAT (Coombs’ test)	Required — ‘interpret the result taking account of the strength of reaction, and whether mother received prophylactic anti-D immunoglobulin during pregnancy’
Full blood count and blood film	Consider, if clinically indicated
Glucose-6-phosphate dehydrogenase	Consider, taking account of ethnic origin
Cultures of blood, urine and/or CSF	Consider, if infection is suspected

A test with two failure modes, in opposite directions

The direct antiglobulin test asks one question: are there immunoglobulin or complement molecules on the surface of this baby’s red cells? It is a good test at answering that question and a poor test at answering the question it is usually asked, which is whether this baby is haemolysing. The gap between the two is where the errors live, and they run in both directions.

A positive result does not mean haemolysis. In one series of 2,484 live births, 426 babies were ABO-incompatible with their mothers and 68 of those — 15.9% — had a positive cord DAT; of the 68, 23 required phototherapy within the first 24 hours. Two in three positive results were not followed by early significant jaundice. The test is genuinely informative as a risk marker: in an independent cohort the odds ratio for phototherapy-requiring hyperbilirubinaemia in DAT-positive infants was 6.78, and blood type incompatibility raised the frequency of hyperbilirubinaemia only in the DAT-positive group. But a risk marker with a positive predictive value of 16.9% is not a diagnosis, and the commonest cause of a positive DAT that means nothing at all is iatrogenic: routine antenatal anti-D immunoglobulin coats an RhD-positive baby’s cells and produces a positive test with no disease behind it. NICE CG98 requires the prophylaxis history to be part of the interpretation, and the AAP’s 2022 risk list is written to exclude it — the neurotoxicity risk factor is a positive DAT specifically when Rh(D) immune globulin was not given.

A negative result does not exclude ABO haemolytic disease. In a nested case-control study of 4,122 newborns containing 44 cases, the DAT’s sensitivity for ABO-HDFN was 65.85%: one case in three was DAT negative. A series that identified cases by elution rather than by the direct test found the proportion far higher still, with 143 of 156 ABO-HDN babies negative on the direct test, an exchange transfusion rate in that group nearly three times that of babies without haemolytic disease, and no significant difference in peak bilirubin between the DAT-negative and DAT-positive cases. The reason is mechanical: A and B antigens on neonatal red cells are weakly expressed and the antibody density is low, so the test runs out of sensitivity before the disease does.

Which is why the specificity of the antibody, and not the DAT grade, is what should change the plan. The antigens associated with severe disease are D, C, c and E, K and k, Fya, Jka and Jkb, M and S; ABO, Fyb and the Lutheran antibodies sit under mild disease; Lewis, I and P1 are not associated with it. The British Society for Haematology names anti-D, anti-K and anti-c as the three carrying significant fetal and neonatal risk. And anti-K deserves separate handling, because it does not work like the others. It suppresses fetal erythropoiesis at the progenitor level rather than destroying circulating cells, which has been shown as in vitro inhibition of Kell-positive burst-forming and colony-forming units. Affected infants have low reticulocyte counts in proportion to the severity of their anaemia, lower bilirubin than the anaemia would predict, and a maternal titre that correlates poorly with how anaemic the baby is; the presentation is fetal anaemia and hydrops rather than jaundice. Every marker that would ordinarily raise the alarm is pushed the wrong way, which is a good argument for following the haemoglobin rather than the bilirubin whenever anti-K is on the report.

Frequently asked questions

Does a positive direct antiglobulin test mean the baby is haemolysing?

No. It means antibody or complement is bound to the baby’s red cells. In one series, 68 of 426 ABO-incompatible newborns had a positive cord DAT and only 23 of those 68 (33.8%) needed phototherapy in the first 24 hours. The positive predictive value for ABO haemolytic disease in a larger case-control study was 16.9%. The haemoglobin, reticulocyte count, blood film and the bilirubin trajectory against the threshold for postnatal age are what establish haemolysis.

Does a negative DAT exclude ABO haemolytic disease of the newborn?

No. Its sensitivity for ABO-HDFN was 65.85% in a nested case-control study of 4,122 newborns, so about one case in three is DAT negative. A series identifying cases by elution found 143 of 156 ABO-HDN babies DAT negative, with no significant difference in peak bilirubin from the DAT-positive cases. Where the clinical picture disagrees with the serology, an eluate can demonstrate antibody the direct test missed.

Why does maternal anti-D prophylaxis matter when reading a newborn DAT?

Because passively acquired anti-D from routine antenatal prophylaxis coats an RhD-positive baby’s red cells and produces a positive DAT with no haemolytic disease behind it. NICE CG98 asks that the result be interpreted taking account of the strength of reaction and whether the mother received prophylactic anti-D immunoglobulin, and AAP 2022 makes its neurotoxicity risk factor a positive DAT specifically when Rh(D) immune globulin was not given during pregnancy.

Which red cell antibodies cause severe haemolytic disease of the fetus and newborn?

The antigens listed as associated with severe disease are D, C, c and E in the Rh system, K and k in Kell, Fya in Duffy, Jka and Jkb in Kidd, and M and S in MNS. ABO, i, Fyb and the Lutheran antibodies are associated with mild disease, and Lewis, I and P1 are not associated with it. The British Society for Haematology singles out anti-D, anti-K and anti-c as carrying significant fetal and neonatal risk.

Why is anti-K different from the other antibodies?

Because it suppresses fetal erythropoiesis at the progenitor level rather than simply destroying circulating red cells, shown as in vitro inhibition of Kell-positive erythroid burst-forming and colony-forming units. Affected infants have low reticulocyte counts corresponding to the severity of their anaemia, lower bilirubin than the anaemia suggests, and a maternal titre that correlates poorly with the degree of anaemia. The typical presentation is severe fetal anaemia and hydrops rather than hyperbilirubinaemia, so the haemoglobin is the number to follow.

What else should be tested alongside the DAT in a jaundiced newborn?

NICE CG98 requires a serum bilirubin, a blood packed cell volume, the blood group of mother and baby, and the DAT itself. It asks you to consider a full blood count and blood film, glucose-6-phosphate dehydrogenase activity taking account of ethnic origin, and cultures of blood, urine or cerebrospinal fluid where infection is suspected. A negative DAT does not exclude non-immune haemolysis: hereditary spherocytosis, G6PD deficiency and pyruvate kinase deficiency all produce a DAT-negative haemolytic jaundice.

Related calculators

References

Abbas SA, Dinardo CL, Godinho CH, et al. Direct antiglobulin test in the differential diagnosis of ABO hemolytic disease of the newborn: an important tool with high negative predictive value. Hematol Transfus Cell Ther. 2024;46(4):450–454 — 4,122 newborns; DAT sensitivity 65.85%, specificity 96.28%, PPV 16.9%, NPV 99.6%.
Chowdhary S, Devi U, Giridhar S. Predicting significant hyperbilirubinemia in ABO incompatibility: is cord direct antiglobulin test useful? Indian J Hematol Blood Transfus. 2022;38(3):591–595 — 68 of 426 ABO-incompatible newborns DAT positive (15.9%), of whom 23 (33.8%) needed phototherapy within 24 hours.
The severity of direct antiglobulin test negative ABO hemolytic disease of newborn: a retrospective analysis at a tertiary children’s hospital. Indian J Hematol Blood Transfus. 2023 — 143 of 156 ABO-HDN cases (91.67%) DAT negative and identified by elution, with an exchange transfusion rate of 4.14%.
Direct antiglobulin test in the prediction of hyperbilirubinemia and predischarge bilirubin levels in infants with mother-infant blood type incompatibility. Pediatr Neonatol. 2021 — 27 of 158 incompatible infants DAT positive (17.1%); odds ratio 6.78 (95% CI 2.38 to 19.33) for hyperbilirubinaemia requiring phototherapy.
National Institute for Health and Care Excellence. Jaundice in Newborn Babies Under 28 Days. NICE clinical guideline CG98; 2010, updated 2023 — the required investigations in significant hyperbilirubinaemia, and the instruction to interpret the DAT against the strength of reaction and maternal anti-D prophylaxis.
Hyperbilirubinemia in newborns: updated guidelines from the AAP. Am Fam Physician. 2023 — synopsis of Kemper AR, et al. Pediatrics. 2022;150(3):e2022058859; a positive DAT as a neurotoxicity risk factor only if Rh(D) immune globulin was not given during pregnancy.
Canadian Blood Services. Clinical Guide to Transfusion: hemolytic disease of the fetus and newborn and perinatal immune thrombocytopenia — the antigen lists for severe, mild and absent HDFN, and the requirement to determine antibody specificity at the time of a positive screen.
British Society for Haematology. Guideline for the Investigation and Management of Red Cell Antibodies in Pregnancy — anti-D, anti-K and anti-c as the antibodies associated with significant fetal and neonatal risk.
Three non-classical mechanisms for anemic disease of the fetus and newborn, based on maternal anti-Kell, anti-Ge3, anti-M, and anti-Jra cases. Transfus Apher Sci. 2020 — anti-K suppression of erythropoiesis at the progenitor level, the low reticulocyte count and lower bilirubin, and the poor titre-to-anaemia correlation; citing Vaughan JI, et al. N Engl J Med. 1998 for the in vitro demonstration.

Medical Disclaimer: The tools and content provided here are for educational and reference purposes only. They are not intended to substitute for professional medical advice, diagnosis, or treatment. Clinical decisions should always be based on the comprehensive assessment of a qualified healthcare professional.